백신 보조제 시장 : 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global vaccine adjuvants market size is expected to reach USD 7.09 Billion in 2034 from USD 4.30 Billion in 2025, growing at a CAGR of 5.72 during 2026-2034.The Global Vaccine Adjuvants market has recorded steady growth driven by rising vaccine research and development activities and increasing adoption of recombinant and subunit vaccines that require enhanced immune stimulation. Expanding immunization programs, coupled with greater preparedness for infectious disease outbreaks, have strengthened demand. Biopharmaceutical collaborations and public health funding initiatives are also accelerating innovation in novel adjuvant platforms, contributing to expanding commercial opportunities and sustained global market expansion.

Key drivers include the need to improve vaccine efficacy in elderly and immunocompromised populations, technological advancements in nanoparticle and toll-like receptor-based adjuvants, and increasing regulatory support for advanced vaccine formulations. Growing investments in pandemic preparedness and therapeutic vaccines further reinforce demand. Moreover, enhanced safety profiles and improved immune response durability are encouraging wider integration of adjuvants across both preventive and therapeutic vaccine pipelines.

Future prospects remain strong as manufacturers focus on combination adjuvants and precision-based immune modulation strategies. Expansion into oncology vaccines, personalized immunization platforms, and emerging markets will generate additional revenue streams. Advancements in large-scale manufacturing and improved understanding of immune mechanisms are expected to strengthen commercialization pathways, positioning the market for sustained long-term growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• Pathogen
• Adjuvant Emulsion
• Particulate
• Combination
• Others

By Application

• Infectious Diseases
• Cancer
• Others

By Administration

• Oral
• Intradermal
• Intranasal
• Intramuscular
• Others

COMPANIES PROFILED

• Adjuvance Technologies Inc., Agenus Inc., Allergy Therapeutics plc, Aurorium, CaPtivate Pharmaceuticals LLC, Creative Diagnostics, Croda International Plc (Brenntag Biosector), CSL Limited, Dynavax Technologies Corporation, EuBiologics Co., Ltd., GSK plc, Hawaii Biotech Inc., InvivoGen, LiteVax B.V., Merck KGaA, Mukta Industries, Novavax, Inc., Oncovir, Inc., OZ Biosciences, Pacific GeneTech Limited, Phibro Animal Health Corporation

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL VACCINE ADJUVANTS MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Pathogen Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Adjuvant Emulsion Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.4. Particulate Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.5. Combination Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL VACCINE ADJUVANTS MARKET: BY APPLICATION 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL VACCINE ADJUVANTS MARKET: BY ADMINISTRATION 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Intradermal Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.4. Intranasal Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.5. Intramuscular Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL VACCINE ADJUVANTS MARKET: BY REGION 2022-2034 (USD MN and Million Doses)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.2.1 By Type
  • 7.2.2 By Application
  • 7.2.3 By Administration
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.3.1 By Type
  • 7.3.2 By Application
  • 7.3.3 By Administration
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.4.1 By Type
  • 7.4.2 By Application
  • 7.4.3 By Administration
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.5.1 By Type
  • 7.5.2 By Application
  • 7.5.3 By Administration
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.6.1 By Type
  • 7.6.2 By Application
  • 7.6.3 By Administration
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL VACCINE ADJUVANTS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Adjuvance Technologies Inc
  • 9.2.2 Agenus Inc
  • 9.2.3 Allergy Therapeutics Plc
  • 9.2.4 Aurorium
  • 9.2.5 CaPtivate Pharmaceuticals LLC
  • 9.2.6 Creative Diagnostics
  • 9.2.7 Croda International Plc (Brenntag Biosector)
  • 9.2.8 CSL Limited
  • 9.2.9 Dynavax Technologies Corporation
  • 9.2.10 EuBiologics Co.Ltd
  • 9.2.11 GSK Plc
  • 9.2.12 Hawaii Biotech Inc
  • 9.2.13 InvivoGen
  • 9.2.14 LiteVax B.V
  • 9.2.15 Merck KGaA
  • 9.2.16 Mukta Industries
  • 9.2.17 NovavaxInc
  • 9.2.18 OncovirInc
  • 9.2.19 OZ Biosciences
  • 9.2.20 Pacific GeneTech Limited
  • 9.2.21 Phibro Animal Health Corporation